Skip to main content
Premium Trial:

Request an Annual Quote

GeneLink's Sales Rise 17 Percent in Q3

NEW YORK (GenomeWeb News) – GeneLink today reported that its third-quarter revenues increased nearly 17 percent to $2.1 million from $1.8 million for the third quarter of 2008, with nearly all of its sales coming from its GeneWize nutritional and dermatological genetic testing services.

GeneLink posted a net loss of $784,000 for the quarter ended Sept. 30, an increase of 53 percent over its net loss of $514,000 for third quarter of 2008.

The Orlando, Fla.-based consumer genomics company said in a filing with the US Securities and Exchange Commission that it will require around $2 million in funding to pursue its marketing strategy. Without those funds, the firm said, it will likely continue to burn through cash and may not be able to continue operations.

GeneLink CEO Monte Taylor said in a statement that the firm has developed a new strategy for lowering the entry price of its LifeMap Me custom nutritional product in an effort to gain customers and increase revenues.

GeneLink finished the quarter with cash and cash equivalents of roughly $426,000.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.